After false start, Merck claims Keytruda approval in early breast cancerMerck & Co’s Keytruda has just picked up its 30th approval from the FDA, and it is a Share XAfter false start, Merck claims Keytruda approval in early breast cancerhttps://pharmaphorum.com/news/after-false-start-merck-claims-keytruda-approval-in-early-breast-cancer/
AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecanAstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) – Share XAZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecanhttps://pharmaphorum.com/news/az-daiichi-unveil-data-from-tnbc-hopeful-datopotamab-deruxtecan/
Boehringer buys NBE for €1.18bn, adding cancer ADC expertiseBoehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics, Share XBoehringer buys NBE for €1.18bn, adding cancer ADC expertisehttps://pharmaphorum.com/news/boehringer-buys-nbe-for-e1-18bn-adding-cancer-adc-expertise/
Immunomedics wows ESMO with breast cancer data revealImmunomedics has revealed the trial data that convinced Gilead to stage a $21 billion takeover, after the biotech’s Share XImmunomedics wows ESMO with breast cancer data revealhttps://pharmaphorum.com/news/immunomedics-wows-esmo-with-breast-cancer-data-reveal/
Gilead pays $21bn for Immunomedics ahead of breast cancer trial readoutGilead has made another big oncology acquisition, paying $21 billion for US biotech Immunomedics and its potential cancer Share XGilead pays $21bn for Immunomedics ahead of breast cancer trial readouthttps://pharmaphorum.com/news/gilead-pays-21bn-for-immunomedics-ahead-of-breast-cancer-trial-readout/
Roche’s Tecentriq flunks triple-negative breast cancer trialRoche’s hopes of extending the use of its PD-L1 inhibitor Tecentriq in triple-negative breast cancer (TNBC) have been Share XRoche’s Tecentriq flunks triple-negative breast cancer trialhttps://pharmaphorum.com/news/roches-tecentriq-flunks-triple-negative-breast-cancer-trial/
NICE and Roche reach funding deal for Tecentriq in triple negative breast cancerNICE has recommended regular NHS funding for Roche’s immunotherapy Tecentriq (atezolizumab) in tough-to-treat advanced triple negative breast cancer in final draft guidance, after a previous rejection. The Share XNICE and Roche reach funding deal for Tecentriq in triple negative breast cancerhttps://pharmaphorum.com/news/nice-okays-funding-for-roches-tecentriq-in-triple-negative-breast-cancer/
Merck & Co squares up to Roche with Keytruda data in triple-negative breast cancerRoche’s Tecentriq still has the market for front-line immunotherapy of triple-negative breast cancer (TNBC) to itself, but maybe Share XMerck & Co squares up to Roche with Keytruda data in triple-negative breast cancerhttps://pharmaphorum.com/news/mercks-squares-up-to-roche-with-keytruda-data-in-triple-negative-breast-cancer/
Merck & Co hopes for foothold in early TNBC after Keytruda trial winMerck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold Share XMerck & Co hopes for foothold in early TNBC after Keytruda trial winhttps://pharmaphorum.com/news/merck-co-hopes-for-foothold-in-early-tnbc/
